News AZ claims EU okay for Imfinzi in bladder cancer AstraZeneca passes another milestone in its journey to rebuild Imfinzi's presence in bladder cancer, a key growth driver for the drug.
News Summit climbs on rumour of $15bn AstraZeneca interest Is AstraZeneca about to join the ranks of pharma companies spending big bucks on PD(L)-1xVEGF bispecific antibodies for cancer?
News AstraZeneca CEO Soriot said to be looking at US listing AstraZeneca chief executive Pascal Soriot is reportedly considering moving the company's stock exchange listing from the UK to the US.
News AZ, Daiichi get Datroway nod in lung cancer on second try AZ and Daiichi Sankyo have claimed FDA approval for Datroway in lung cancer after switching indications for the TROP2-directed drug.
News AZ taps Chinese firm CSPC's AI acumen in $5.2bn+ alliance AstraZeneca taps China's CSPC Pharma for new drug candidates a second time – and the latest AI-focused alliance is a big one.
News Beyfortus now has a direct rival after FDA OK for Enflonsia MSD could soon enter the US market for drugs used to protect infants from RSV infections, setting up a rivalry with AstraZeneca/Sanofi's Beyfortus.
Digital Chaos & opportunity: Dr Adam Brown unpacks US health policy Dive into our video interview with Dr Adam Brown as he unpacks the chaos and opportunity shaping US health policy.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
